文献速递淋巴瘤

85岁及以上主要淋巴瘤亚型患者的临床特征与结局:北欧淋巴瘤组研究

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study.
PubMed 文献 · Br J Haematol · 2020-11-24

该研究基于丹麦和瑞典淋巴瘤登记库,纳入2347例年龄≥85岁的淋巴瘤患者,采用相对生存率(RS)评估结局。惰性淋巴瘤患者2年RS为77%,接受积极治疗与未接受者2年RS无显著差异。结论认为年龄本身不应作为治疗禁忌。

要点

  • 侵袭性淋巴瘤≥85岁患者接受积极治疗与更优2年相对生存率相关。
  • 惰性淋巴瘤≥85岁患者接受积极治疗未显示2年相对生存率获益。
  • 年龄本身不应被视为淋巴瘤治疗的禁忌证。

核心结论

  • ≥85岁淋巴瘤患者中,侵袭性淋巴瘤接受积极治疗与改善的结局相关,年龄本身不应作为治疗禁忌。
  • 惰性淋巴瘤患者接受积极治疗未显示2年相对生存率优于未治疗者。

研究设计与样本

  • 基于丹麦(2000-2016年)和瑞典(2007-2013年)淋巴瘤登记库的回顾性研究,纳入2347例年龄≥85岁的淋巴瘤患者,采用相对生存率评估结局。

主要发现

  • 侵袭性淋巴瘤患者2年相对生存率总体为38%(95%CI 35-42%),其中845例(66%)接受积极治疗。
  • 惰性淋巴瘤患者2年相对生存率为77%(95%CI 72-82%),383例(46%)在诊断时接受积极治疗。
  • 惰性淋巴瘤接受积极治疗者2年相对生存率为75%(95%CI 67-81%),未接受积极治疗者为83%(95%CI 74-89%)。

临床怎么用

  • 对≥85岁侵袭性淋巴瘤患者,不应仅因年龄而排除积极治疗,治疗与更优相对生存率相关。
  • 对≥85岁惰性淋巴瘤患者,积极治疗未显示2年相对生存率优势,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a lack of data regarding treatment and prognosis for the growing group of oldest old patients with lymphoma. Therefore, we studied 2347 patients aged ≥85 years from the Danish and Swedish lymphoma registers 2000-2016 (Denmark) and 2007-2013 (Sweden). Outcome was assessed using relative survival (RS). The 2-year RS overall for patients with aggressive lymphomas was 38% [95% confidence interval (CI) 35-42%], of whom 845 (66%) patients received active treatment (chemotherapy, radiotherapy, immunotherapy, other). For aggressive lymphomas, not receiving active treatment was associated with an inferior 2-year RS of 12% (95% CI 9-17%) compared to 49% (95% CI 45-53%) for patients who received active treatment (excess mortality rate ratio 2·84, 95% CI 2·3-3·5; P < 0·0001). For patients with indolent lymphoma, the 2-year RS was 77% (95% CI 72-82%). Here, 383 (46%) patients received active treatment at diagnosis, but did not have better 2-year RS (75%, 95% CI 67-81%) compared to those who did not receive active treatment (83%, 95% CI 74-89%). We conclude that outcomes for the oldest old patients with lymphoma are encouraging for several subtypes and that active treatment is associated with improved outcome amongst the oldest old patients with aggressive lymphomas, indicating that age itself should not be a contraindication to treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wästerlid T, Oren Gradel K, Eloranta S, et al. Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study. Br J Haematol. 2020. PMID: 33236363. doi:10.1111/bjh.17250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。